Thermo Fisher Scientific Inc. $TMO Stock: Farther Finance Advisors LLC Grows Stake

Key Points

• Farther Finance Advisors increased its Thermo Fisher Scientific stake by 13.2% in the third quarter, while institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly earnings of $6.03 per share, beating estimates of $5.71, as revenue rose 10.5% year over year to $11.99 billion. The company guided to fiscal 2026 EPS of $24.93–$25.33.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $634.86, though Wells Fargo downgraded the stock to “underweight.” Insiders sold $44.1 million worth of shares over the past three months.

Farther Finance Advisors LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,829 shares of the medical research company's stock after acquiring an additional 1,731 shares during the quarter. Farther Finance Advisors LLC's holdings in Thermo Fisher Scientific were worth $10,010,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TMO. Bank OZK purchased a new stake in Thermo Fisher Scientific during the second quarter valued at $1,096,000. Ausdal Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $456,000. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. German American Bancorp Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $814,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.0%

NYSE:TMO opened at $658.23 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a 50-day simple moving average of $627.39 and a 200-day simple moving average of $541.36. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $694.33. The firm has a market cap of $243.38 billion, a P/E ratio of 35.41, a P/E/G ratio of 2.73 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc Casper sold 275 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company's stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "overweight" rating for the company. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday. Finally, Wells Fargo & Company cut shares of Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $634.86.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.